Print
Robert Kratzke, MD
Robert Kratzke, MD
Request Appointment
Masonic Cancer Clinic
Masonic Memorial Building
First Floor, Suite M100
424 Harvard St. SE
Minneapolis, MN 55455
612-625-5411

Sees Patients at:

Philosophy of Care:

The University of Minnesota Thoracic Oncology Program strives to deliver high quality, state-of-the-art, integrated care using surgery, medicine, and radiation. All lung cancer and mesothelioma patients that come to us for care or information are reviewed by representatives of all three treatment modalities to offer the best outcome for our patients.

Medical Title:

Academic Appointments:

Specialties:

Clinical Interests:

Languages Spoken:

Education:

Board Certifications:

Research Interests:

2004 - The John Skoglund Chair in Lung Cancer Research

Patel, MR, Jacobson, BA, De, A, Frizelle, SP, Janne, P, Thumma, SC, Whitson, BA, Farassati, F, Kratzke, RA. Ras pathway activation in malignant mesothelioma. Journal of Thoracic Oncology, 2007 Sep;2(9):789-95.

Kirstein, MN, Wieman, KM, Williams, BW, Fisher, JE, Marker, PH, Le, CT, Yee, D., Kratzke, RA. Short vs. Continuous Gemcitabine Treatment of Non-Small Cell Lung Cancer in an in vitro Cell Culture Bioreactor System. Lung Cancer. 2007 Nov;58(2):196-204.

Edelman, MJ, Watson, D, Wang, X, Morrison, C, Kratzke, RA, Jewell, S, Hodgson, L, Mauer, A, Graziano, SL, Masters, GA, Bedor, M, Green, MJ, Vokes, EE. Eicosanoid modulation in advanced lung cancer: COX-2 expression is a positive predictive factor for celecoxib + chemotherapy. Journal of Clinical Oncology. 2008 Feb 20;26(6):848-55.

Kratzke, RA, Wang, X., Wong, L, Kratzke, MG, Green, MR, Vokes, EE, Vogelzang, NJ, Kindler, HL, Kern, JA, for the Cancer and Leukemia Group B. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a; Results of Cancer and Leukemia Group B 159904. J Thorac Oncol. 2008 Apr;3(4):417-21.

Jacobson, BA, De, A, Kratzke, MG, Patel, MR, Jay-Dixon, J, Whitson, BA, Sadiq, AA, Bitterman, PB, Polunovsky, VA, Kratzke, RA. Activated 4E-BP1 represses tumorigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. British Journal of Cancer. 2009 Aug 4;101(3):424-31.

Dudek AZ, Lesniewski-Kmak K, Larson T, Dragnev K, Isaksson R, Gupta V, Maddaus MA, Kratzke RA. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer. Journal of Thoracic Oncology. 2009 Aug;4(8):969-75.

Klein, MA, Mayo, KH, Kratzke, RA. p16INK4a Peptide mimetics identified via virtual screening. Bioorganic & Medicinal Chemistry Letters. 2010 Jan 1;20(1):403-5.

Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010 Aug;17(8):550-8.

Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol. 2010 Jun;5(6):810-7.

Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL.A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct;5(10):1655-61.

 
 Visit Other Fairview Sites 
 
 
(c) 2012 Fairview Health Services. All rights reserved.